Pegasys and copegus

Common Questions and Answers about Pegasys and copegus

pegasys

Avatar m tn Table 3, Table 4, Table 5, and Table 6 provide guidelines for dose modifications and discontinuation of PEGASYS/COPEGUS based on laboratory abnormalities, patient’s depression status, and cardiac status. Adult Patients When dose modification of PEGASYS is required for adverse reactions (clinical and/or laboratory), initial dose reduction to 135 mcg (which is 0.75 mL for the vials or adjustment to the corresponding graduation mark for the prefilled syringes) is recommended.
Avatar f tn has anyone treated with Pegasys and Copegus instead of Sovaldi and Ribavarin, and if so are the results the same?
Avatar f tn i am a non responder,after 2 previous tratments with other interferons,now after having a liver biopsy my dr wants me to go on pegasys with copegus, he wants to prescribe the 180mcg/0.5ml shot along which is prefilled but he wants me to take some of the other prefilled shot which would make it more than the normal 180 mcg. i did not ask him exactly how much it will total cause i have doubts about this,i have never heard of this. and may just stick with the 180 once a week.
Avatar f tn GS-9256 placebo 8 Recruiting A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Condition: Hepatitis C, Chronic Interventions: Drug: Tegobuvir (GS-9190); Drug: GS-9451; Biological: Pegasys®; Drug: Copegus®; Drug: Tegobuvir placebo; Drug: GS-9451 placebo Good luck.
Avatar f tn SVR for Pegasys plus Copegus combination therapy is 44-51% for genotype 1, and 70-82% for genotypes 2 through 6. Pegasys is a ready-made solution that is dosed at 180µg regardless of a person's weight. The FDA has also approved Pegasys for treatment of chronic hepatitis B and Pegasys plus Copegus for the treatment of people with HIV and hepatitis C coinfection.
476246 tn?1418870914 (1-4) An analysis of a major study (ACCELERATE) which evaluated the efficacy and safety of 16 weeks vs. 24 weeks of treatment with Pegasys/Copegus in patients with genotype 2 or 3 HCV -- showed that a similar number of patients achieved a cure (82% versus 90% respectively). In patients with low virus levels before treatment and a rapid virological response (undetectable virus 4 weeks after starting treatment), the cure rates for 16 and 24 weeks of treatment were essentially identical (89% vs.
Avatar f tn * Safety and tolerability for the 4-week treatment period were similar for R7128 with Pegasys plus Copegus compared to placebo with Pegasys plus Copegus. There were no serious adverse events reported during the 4-week treatment period, and most of the adverse events reported were of mild to moderate intensity.
154668 tn?1290115995 R7128 has shown potent in vivo activity against all of the most common HCV genotypes (1, 2 and 3). R7128 was safe and well-tolerated when given with PEGASYS and COPEGUS for up to 28 days. About PEGASYS PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic HCV who have compensated liver disease and have not previously been treated with interferon alpha.
3867523 tn?1348949685 Patients treated for 24 weeks with PEGASYS and 800 mg COPEGUS were observed to have lower incidence of serious adverse events (3% vs 10%), Hgb <10 g/dL (3% vs 15%), dose modification of PEGASYS (30% vs 36%) and COPEGUS (19% vs 38%) and of withdrawal from treatment (5% vs 15%) compared to patients treated for 48 weeks with PEGASYS and 1000 mg or 1200 mg COPEGUS. On the other hand the overall incidence of adverse events appeared to be similar in the two treatment groups.
Avatar f tn RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche.
Avatar m tn Do you know any tx for anemia caused by ribavirin other than 1) procrit or 2) greatly reducing ribavirin intake for patients on telaprevir, with pegasys, and ribavirin that will increase hemoglobin levels?
Avatar m tn (1-4) An analysis of a major study (ACCELERATE) which evaluated the efficacy and safety of 16 weeks vs. 24 weeks of treatment with Pegasys/Copegus in patients with genotype 2 or 3 HCV -- showed that a similar number of patients achieved a cure (82% versus 90% respectively). In patients with low virus levels before treatment and a rapid virological response (undetectable virus 4 weeks after starting treatment), the cure rates for 16 and 24 weeks of treatment were essentially identical (89% vs.
Avatar f tn I have been on the Pegasys shot and Copegus pills since May 11th, with one shot a week on Saturdays and 5 pills a day (2 in the morning & 3 in the evening) but he has halted my treatment until I get on the Neuopogen and the Procrit. The Roche company helps me pay for the Pegasys and the Copegus but I can't afford either the Neuopogen and the Procrit. My doctor said that I will be on both of these new meds as long as I am on the interferon treatment.
Avatar n tn Pegasys (Peginterferon alfa-2a (injection) is distributed by Roche Pharmaceuticals and is taken with COPEGUS (ribavirin pills). It is a medicine that works by slowing down the growth of the virus. COPEGUS should be taken with PEGASYS to fight the virus. Schering-Plough's PEGINTRON (peginterferon alfa-2b) Powder for Injection and INTRON A (interferon alfa-2b, recombinant) for Injection, or INTRON A therapy should be taken with REBETOL (ribavirin, USP) Capsules.
476246 tn?1418870914 Just got back from my appointment, my doc will be treating me with 180 Pegasys and 800 Copegus for my weight and being geno 3. It corresponds to ca 14mg/kilo. I weigh between 56 and 58, it's going up and down all the time. 56 kg is around 124lb, I think. I believe 800 should be suffiecient. Here is something it says on the insert of Copegus. I believe that is what they go after.
Avatar n tn I was told the cost for a 48 wk treatment of peginterferon/ribaviron (pegasys and copegus) was around $30,000. I am a self employed single wage earner with no medical insurance. I spoke with my Dr. and because of my income they helped me apply to Pegassist through Genentech. I get all my meds at no charge but I am responsible for the cost of all lab work through the 11 months and dr. office calls.
678069 tn?1254422777 I am about to start treatment with Pegasys and Copegus, and I was wondering one thing....Does anyone know what percentage of people on this treatment experience hair loss? Ive read a lot and hair loss seems to be a pretty common side effect. But just how common is what Im wondering. I believe I can handle the other stuff (Flu-like symptoms, depression, etc). Its the hair loss thing that really has me worried. Oddly enough, I have shaved my head since I was 12.
Avatar m tn I am on pegasys but that is because I am in a trial for a polymerase inhibitor called R7128 which is done in conjunction with Roche, who makes pegasys and copegus. The trial gives all three drugs. For what it is worth I was told by others that pegasys sides were more tolerable than PegIntron but you know what, if they are it still *****! LOL I hope this helps and welcome to the forum.
Avatar m tn Given the fact that you are a geno 1 - that is an excellent response to tx considering you're on SOC. (peg & riba) Way to go!!!
Avatar f tn patients with genotypes 2 and 3 for 24 weeks with Pegasys 180 microg/week plus Copegus 800 mg/day. RESULTS: 132 patients were enrolled in the study: 85 HCV mono-infected (38: genotypes 1 and 4; 47: genotypes 2 and 3), 47 HIV-HCV co-infected patients (23: genotypes 1 and 4; 24: genotypes 2 and 3). In an intention-to-treat analysis, SVR for genotypes 1 and 4 was observed in 58% of HCV mono-infected http://www.ncbi.nlm.nih.